Business Description
JW (Cayman) Therapeutics Co Ltd
ISIN : KYG5210T1040
Share Class Description:
HKSE:02126: Ordinary SharesCompare
Compare
Traded in other countries / regions
02126.Hong KongJWCTF.USAJNY.Germany IPO Date
2020-11-03Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.28 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.62 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.22 | |||||
| Beneish M-Score | -3.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 50.9 | |||||
| 3-Year EPS without NRI Growth Rate | 52.6 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | -24.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 13.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 48.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.22 | |||||
| 9-Day RSI | 37.97 | |||||
| 14-Day RSI | 40.28 | |||||
| 6-1 Month Momentum % | -38.26 | |||||
| 12-1 Month Momentum % | -55.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | |||||
| Quick Ratio | 2.76 | |||||
| Cash Ratio | 2.69 | |||||
| Days Inventory | 179.63 | |||||
| Days Sales Outstanding | 11.52 | |||||
| Days Payable | 37.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | -1.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.4 | |||||
| Operating Margin % | -290.64 | |||||
| Net Margin % | -363.75 | |||||
| FCF Margin % | -213.37 | |||||
| ROE % | -35.44 | |||||
| ROA % | -27.75 | |||||
| ROIC % | -36.33 | |||||
| ROC (Joel Greenblatt) % | -180.71 | |||||
| ROCE % | -31.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.88 | |||||
| PB Ratio | 0.34 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| EV-to-EBIT | -0.03 | |||||
| EV-to-EBITDA | -0.03 | |||||
| EV-to-Revenue | 0.1 | |||||
| EV-to-FCF | -0.06 | |||||
| Price-to-Net-Current-Asset-Value | 1.13 | |||||
| Price-to-Net-Cash | 1.36 | |||||
| Earnings Yield (Greenblatt) % | -3333.33 | |||||
| FCF Yield % | -73.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JW (Cayman) Therapeutics Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 187.652 | ||
| EPS (TTM) (HK$) | -1.652 | ||
| Beta | 1.86 | ||
| Volatility % | 83.19 | ||
| 14-Day RSI | 40.28 | ||
| 14-Day ATR (HK$) | 0.081266 | ||
| 20-Day SMA (HK$) | 1.354 | ||
| 12-1 Month Momentum % | -55.21 | ||
| 52-Week Range (HK$) | 1.19 - 3.32 | ||
| Shares Outstanding (Mil) | 415.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JW (Cayman) Therapeutics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JW (Cayman) Therapeutics Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
JW (Cayman) Therapeutics Co Ltd Frequently Asked Questions
What is JW (Cayman) Therapeutics Co Ltd(HKSE:02126)'s stock price today?
The current price of HKSE:02126 is HK$1.31. The 52 week high of HKSE:02126 is HK$3.32 and 52 week low is HK$1.19.
When is next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126)?
The next earnings date of JW (Cayman) Therapeutics Co Ltd(HKSE:02126) is .
Does JW (Cayman) Therapeutics Co Ltd(HKSE:02126) pay dividends? If so, how much?
JW (Cayman) Therapeutics Co Ltd(HKSE:02126) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers